Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men

Journal of Nuclear Medicine

Volumn 54, Issue 6, 2013, Pages 867-872

  Roivainen, Anne ^a   Kähkönen, Esa ^a   Luoto, Pauliina ^a   Borkowski, Sandra ^b   Hofmann, Birte ^b   Jambor, Ivan ^a   Lehtiö, Kaisa ^a   Rantala, Tuija ^a   Rottmann, Antje ^b   Sipilä, Henri ^a   Sparks, Rick ^c   Suilamo, Sami ^a   Tolvanen, Tuula ^a   Valencia, Ray ^b   Minn, Heikki ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b BAYER PHARMA AG   (Germany)

^c CDE Dosimetry Services Inc   (United States)

Author keywords

68Ga; Dosimetry; PET; Pharmacokinetics; Radiometabolism; Whole body distribution

Indexed keywords

BAY 86 7548; BOMBESIN ANTAGONIST; DOTA GA 68; DRUG METABOLITE; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLADDER WALL; BLOOD SAMPLING; COMPUTED TOMOGRAPHY SCANNER; DOSE RESPONSE; DOSIMETRY; DRUG ADSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN EXPERIMENT; MALE; METABOLIC RATE; NORMAL HUMAN; PANCREAS; PET SCANNER; PRIORITY JOURNAL; RADIOACTIVITY; WHOLE BODY CT; WHOLE BODY PET;

68GA; DOSIMETRY; PET; PHARMACOKINETICS; RADIOMETABOLISM; WHOLE-BODY DISTRIBUTION;

BOMBESIN; HEALTH; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; RADIOCHEMISTRY; RADIOMETRY; SAFETY; TISSUE DISTRIBUTION;

EID: 84878667746     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.114082     Document Type: Article

References (20)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
3. 11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18-23.
4. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology. 2001;57:108-111. (Pubitemid 32065829)
5. 18fluorine-labeled deoxyglucose. J Urol. 1996;155:994-998.
6. 1H-MR spectroscopy. J Nucl Med. 2010;51:1676-1683.
7. 11C-Acetate PET/CT in localized prostate cancer: a study with MR imaging and histopathologic correlation. J Nucl Med. 2012;53:538-545.
8. 11C] choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res. 2011;17:3751-3759.
9. 125I-[D- TYR6, β-ALA11, PHE13, NLE14]Bombesin(6-14). Clin Cancer Res. 2002;8:1139-1146.
10. Mansi R, Wang X, Forrer F, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging. 2011;38:97-107.
11. Teräs M, Tolvanen T, Johansson JJ, Williams JJ, Knuuti J. Performance of the new generation of whole-body PET/CT scanners: Discovery STE and Discovery VCT. Eur J Nucl Med Mol Imaging. 2007;34:1683-1692. (Pubitemid 47476933)
12. Stabin MG, Sparks RB, Crowe EB. OLINDA/EXM: the second generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027. (Pubitemid 43733519)
13. Siegel JA, Thomas SR, Stubbs JB, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40 (suppl):37S-61S. (Pubitemid 29077103)
14. International Commission on Radiological Protection (ICRP). 1990 Recommendations of the International Commission on Radiological Protection. ICRP Publication 60. New York, NY: Pergamon Press; 1991.
15. Jensen RT, Battey JF, Spindel ER, et al. International union of pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev. 2008;60:1-42. (Pubitemid 351439216)
16. 68Ga-DOTATOC PET/CT examinations. Nuklearmedizin. 2009;48:201-207.
17. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008;35:72-79.
18. 68Ga-NOTA-RGD, a positron emission tomography agent for angiogenesis imaging. Cancer Biother Radiopharm. 2012;27:65-71.
19. International Commission on Radiological Protection (ICRP). Radiation doses to patients from radiopharmaceuticals: a third amendment to ICRP publication 53. ICRP publication 106. Ann ICRP. 2008;38:1-198.
20. International Conference on Harmonisation; Guidance on M3(R2) nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals; availability. Notice. Fed Regist. 2010;75:3471-3472.